Compare Aurora Cannabis Inc (ACB) vs Kyndryl Holdings Inc (KD) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Kyndryl Holdings (KD) trades at $12.39, up 1.14% on the day, with a bullish technical signal from moving averages. The company reported revenue of $15.06B for 2025, achieving a net income of $252M, marking a return to profitability after losses in prior years. Recent news includes a partnership with Microsoft for sovereignty solutions and new executive appointments, but also legal investigations into the company's disclosures following a significant stock price decline earlier in 2026.

The outlook is mixed; improving cash flow and a low EV/EBITDA of 3.19 suggest undervaluation, but recent earnings misses and legal overhangs pose risks. Analyst consensus is a 'Hold' with a $14.33 price target, implying modest upside. Key investor focus is on the Q2 2026 earnings report due August 5, 2026, for confirmation of the profitability turnaround.